obesity

News

The largest observational study of GLP-1 weight-loss drugs suggests their benefits could be wide-ranging, but there are some risks to consider.

News

Novo Nordisk's high-dose version of semaglutide boosts its weight-loss ability, but it still can't match its main rival in the obesity market.

News

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity therapies.

News

Experts think the current way of defining obesity based on BMI isn't nuanced enough to gauge health and the need for weight-loss therapies.

R&D

The pharmaceutical landscape in 2024 was undeniably shaped by the remarkable rise of GLP-1 receptor agonists.

News

Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs.